International review of neurobiology最新文献_第4页

Emerging evidence for pregnane steroid therapeutics for alcohol use disorders. 孕烷类固醇治疗酒精使用障碍的新证据。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.irn.2024.07.004

A Leslie Morrow, Minna H McFarland, Todd K O'Buckley, Donita L Robinson

{"title":"Emerging evidence for pregnane steroid therapeutics for alcohol use disorders.","authors":"A Leslie Morrow, Minna H McFarland, Todd K O'Buckley, Donita L Robinson","doi":"10.1016/bs.irn.2024.07.004","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.004","url":null,"abstract":"Many lines of research have suggested that the neuroactive pregnane steroids, including pregnenolone, progesterone, and allopregnanolone ([3α,5α]-3-hydroxypregnan-20-one, 3α,5α-THP), have therapeutic potential for treatment of alcohol use disorders (AUDs). In this chapter, we systematically address the preclinical and clinical evidence that supports this approach for AUD treatment, describe the underlying neurobiology of AUDs that are targeted by these treatments, and delineate how pregnane steroids may address various components of the disease. This review updates the theoretical framework for understanding how endogenous steroids that modulate the effects of alcohol, stress, excitatory/inhibitory and dopamine transmission, and the innate immune system appear to play a key role in the prevention and mitigation of AUDs. We further discuss newly discovered limitations of pregnane steroid therapies as well as the challenges that are inherent to development of endogenous compounds for therapeutics. We argue that overcoming these challenges presents the opportunity to help millions who suffer from AUDs across the world.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"59-96"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Historical perspective on the therapeutic potential of cannabidiol. 从历史角度看大麻二酚的治疗潜力。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-06-27 DOI: 10.1016/bs.irn.2024.03.008

Francisco Silveira Guimarães

引用次数: 0

Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption. 磷脂酰乙醇（B-PEth）及其他直接和间接的酒精消费生物标志物。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1016/bs.irn.2024.03.004

Andrea de Bejczy

引用次数: 0

Advances in symptom management and in monitoring disease progression in motor neuron disease. 运动神经元病症状管理和疾病进展监测方面的进展。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1016/bs.irn.2024.04.004

Esther Hobson, Christopher McDermott

引用次数: 0

Exploring neuroinflammation: A key driver in neuropathic pain disorders. 探索神经炎症：神经性疼痛疾病的关键驱动因素

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-11-07 DOI: 10.1016/bs.irn.2024.10.009

Paulina S Scheuren, Margarita Calvo

引用次数: 0

Investigating affective neuropsychiatric symptoms in rodent models of Parkinson's disease. 研究帕金森病啮齿动物模型中的情感神经精神症状。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2023-09-15 DOI: 10.1016/bs.irn.2023.08.006

Laura Boi, Gilberto Fisone

{"title":"Investigating affective neuropsychiatric symptoms in rodent models of Parkinson's disease.","authors":"Laura Boi, Gilberto Fisone","doi":"10.1016/bs.irn.2023.08.006","DOIUrl":"10.1016/bs.irn.2023.08.006","url":null,"abstract":"Affective neuropsychiatric disorders such as depression, anxiety and apathy are among the most frequent non-motor symptoms observed in people with Parkinson's disease (PD). These conditions often emerge during the prodromal phase of the disease and are generally considered to result from neurodegenerative processes in meso-corticolimbic structures, occurring in parallel to the loss of nigrostriatal dopaminergic neurons. Depression, anxiety, and apathy are often treated with conventional medications, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and dopaminergic agonists. The ability of these pharmacological interventions to consistently counteract such neuropsychiatric symptoms in PD is still relatively limited and the development of reliable experimental models represents an important tool to identify more effective treatments. This chapter provides information on rodent models of PD utilized to study these affective neuropsychiatric symptoms. Neurotoxin-based and genetic models are discussed, together with the main behavioral tests utilized to identify depression- and anxiety-like behaviors, anhedonia, and apathy. The ability of various therapeutic approaches to counteract the symptoms observed in the various models is also reviewed.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"174 ","pages":"119-186"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence. 羟丁酸钠：对治疗酒精戒断综合征和酒精依赖症的疗效和安全性进行全面审查。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-20 DOI: 10.1016/bs.irn.2024.07.005

Julien Guiraud, Wim van den Brink

{"title":"Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence.","authors":"Julien Guiraud, Wim van den Brink","doi":"10.1016/bs.irn.2024.07.005","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.005","url":null,"abstract":"Alcohol dependence (AD) significantly impacts public health, affecting 3.4% of people aged 18-64 and contributing to around 12% of overall mortality. Individuals with AD have a markedly reduced life expectancy, dying up to 28 years earlier than the general population. Current treatments for AD show limited efficacy, with many patients not responding to these interventions, highlighting the need for new therapeutic options with novel mechanisms of action. Sodium oxybate (SMO), the sodium salt of GHB, is one such candidate, pharmacologically similar to alcohol; it acts on several neurotransmitters including GABA, potentially mitigating withdrawal symptoms and craving for alcohol. SMO has been clinically used in Italy and Austria since the 1990s, approved for treating alcohol withdrawal syndrome (AWS) and for maintaining abstinence in AD patients. Several randomized clinical trials (RCTs) and meta-analyses showed evidence of SMO to be effective and safe in these indications. For AWS, SMO was more effective than placebo and as effective as benzodiazepines in reducing withdrawal symptoms. For maintaining abstinence, SMO significantly improved continuous abstinence duration and abstinence rate compared to placebo. Comprehensive clinical data indicate that SMO is well-tolerated, with main adverse effects being mild, such as dizziness and vertigo, and serious adverse events being rare. The effectiveness and safety of SMO, coupled with its approval in two EU countries affirm its potential as a treatment option for AD, particularly in severe cases. Further RCTs, especially with stratification by severity of dependence, are suggested to refine our understanding of its efficacy across different patient subgroups.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"213-281"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy. 酒精依赖症患者的替代疗法：作用机制和疗效。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-16 DOI: 10.1016/bs.irn.2024.03.005

Julien Guiraud, Rainer Spanagel, Wim van den Brink

{"title":"Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy.","authors":"Julien Guiraud, Rainer Spanagel, Wim van den Brink","doi":"10.1016/bs.irn.2024.03.005","DOIUrl":"10.1016/bs.irn.2024.03.005","url":null,"abstract":"New approaches for the treatment of alcohol dependence (AD) may improve patient outcomes. Substitution maintenance therapy is one of the most effective treatment options for opioid and nicotine use disorders. So far, there has been little attention to substitution therapy for the treatment of AD. Here, we explain the mechanistic foundations of alcohol substitution maintenance therapy. Alcohol has many primary targets in the brain (and other organs) and the physical interaction of ethanol molecules with these specific ethanol-sensitive sites on a variety of ionotropic receptors (e.g. GABA-A, NMDA, and nicotinic acetylcholine (nACh) receptors) and ion channels provides the rationale for substitution. As such, a variety of compounds can interact with those ethanol-sensitive sites and can thus substitute for some of the effects of alcohol. For some of these compounds, alcohol discrimination studies have shown their substitution potential. Accordingly, potential substitution treatments include agonists acting at GABA receptors such as sodium oxybate, baclofen and benzodiazepines, NMDA receptor antagonists such as ketamine and memantine, or nAChRs agonists such as varenicline. All these compounds are already approved for other indications and we present clinical evidence for these drugs in the treatment of alcohol withdrawal syndrome (AWS) and in the long-term treatment of AD, and outline future steps for their acceptance as substitution treatment in AD. Finally, we discuss the substitution approach of managed alcohol programs for the most severely affected homeless populations. Results showed that sodium oxybate is probably the closest to a substitution therapy for AD and is already approved for the treatment of AWS and in the long-term treatment of AD in some countries. In conclusion, we argue that better AD treatment can be provided if substitution maintenance treatments for alcohol are implemented at a similar scale as for opioid and nicotine use disorder.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"175 ","pages":"187-239"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives. 减少酒精的危害：营养干预和功能性酒精替代品。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1016/bs.irn.2024.03.001

Delia Belelli, Antonio Riva, David John Nutt

引用次数: 0

GABAergic compounds for the treatment of alcohol use disorder. 用于治疗酒精使用障碍的 GABA 能化合物。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-08-17 DOI: 10.1016/bs.irn.2024.08.001

Laís F Berro, James K Rowlett, Donna M Platt

{"title":"GABAergic compounds for the treatment of alcohol use disorder.","authors":"Laís F Berro, James K Rowlett, Donna M Platt","doi":"10.1016/bs.irn.2024.08.001","DOIUrl":"10.1016/bs.irn.2024.08.001","url":null,"abstract":"Decades of research have implicated the gamma-aminobutyric acid (GABA)ergic system as one of the main mediators of the behavioral effects of alcohol. Of importance, the addiction-related effects of alcohol also have been shown to be mediated in part by GABAergic systems, raising the possibility that pharmacotherapies targeting GABAergic receptors may be promising candidates for the treatment of alcohol use disorder (AUD). Alcohol modulates the activity of GABAA and GABAB receptors, and studies show that compounds targeting some of those receptors may decrease the addiction-related behavioral effects of alcohol. Specifically, drugs that share similar pharmacological properties with alcohol, such as positive allosteric modulators (PAMs) of GABAA and GABAB receptors, have been proposed as substitution therapies for AUD. Available evidence also suggests that negative allosteric modulators (NAMs) of GABAergic receptors may be potential therapeutics for AUD, although this effect is selective for specific receptor subtypes. Therefore, this Chapter reviews the available evidence on the use of GABAergic compounds for the treatment of AUD. Several GABAA and GABAB ligands show promising results, with a particularly positive therapeutic profile demonstrated for α5GABAA receptor NAMs, α4/6δGABAA receptor modulators (both positive and negative, including neurosteroids), and GABAB receptor PAMs. As newer and better GABAergic compounds become available, future research should focus on understanding how these ligands can modulate different clinical symptoms of AUD, with potential new areas of research encompassing alcohol withdrawal syndrome and AUD-related insomnia.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"383-399"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0